Empagliflozin for non-alcoholic fatty liver disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 8 Mar 2019: Trial registered, NCT03867487

The trials

NCT03867487: SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease

State
Not started
Phase
Phase 2
People
40 planned
Started
1 May 2027
Primary completion
1 Jan 2028
Arms
Study intervention
Results
None posted
  1. 8 Mar 2019: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Drug.

Also known as Empagliflozin 10 MG, Empagliflozin 10 MG OD, Empagliflozin 25 MG, Empagliflozin10Mg Tab, Glyxambi component empagliflozin, Jardiance, Trijardy xr component empagliflozin.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.